A $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP ...

Inhibitor Therapeutics, Inc. (OTCMKTS:INTI – Get Free Report) was the recipient of a large increase in short interest during the month of December. As of December 15th, there was short interest ...

Ruxolitinib was approved based on the COMFORT trials. 6,7 COMFORT-I [NCT00952289] was a randomized phase 3 trial that ...

Eoptic Inc. has been awarded a $1.25 million Direct-to-Phase II Small Business Innovation Research (SBIR) contract by the U.S ...

AbbVie (NYSE: ABBV) recently announced new results from two ongoing clinical trials evaluating epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, in adult ...

The City of Grand Junction announced it is constructing two new Level 2 Electric Vehicle charging stations and has replaced three city-owned charging facilities with new software, EvGateway.

Phnom Penh's major new Morodok Tocho flyover is nearing completion, but traffic has already been radically reduced by its ...

R-targeted therapy PMB-CT01 for treating B-cell malignancies, including heavily pretreated follicular lymphoma.

Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial,” ...

Company aligned with FDA on CMC strategy and requirements in preparation of Phase 3 pivotal trial of IMNN-001Vertical integration of major ...

Opus Genetics (IRD) announced that it has reached agreement with the U.S. Food and Drug Administration, FDA, on a Special Protocol Assessment, ...

A RECENT Phase II clinical trial has revealed promising results for men with low-grade ... could reduce prostate cancer ...